13.10.2021 • NewsAstraZeneca

AstraZeneca’s Alexion Buys Caelum Biosciences

AstraZeneca’s rare diseases unit Alexion has taken full control of Caelum Biosciences, gaining access to another rare disease drug, CAEL-101, which is a potential treatment for light chain amyloidosis (AL) that has been granted Fast Track status by the US Food and Drug Administration (FDA).

“With a median survival time of less than 18 months following diagnosis, there is an urgent need for new treatments for this devastating disease,” said Alexion’s CEO Marc Dunoyer. “CAEL-101 has the potential to be the first therapy to target and remove amyloid deposits from organ tissues, improve organ function and, ultimately, lead to longer lives for these patients.”

Alexion, acquired by AstraZeneca in July for $39 billion, paid about $150 million to acquire the remaining equity in Caelum and has committed to making additional payments of up to $350 million contingent on achieving regulatory and commercial milestones. It previously took a minority stake in Caelum when the companies entered into a collaboration in January 2019 to develop CAEL-101.

AL is a rare and life-threatening disease caused by defective proteins – or amyloids – building up in organs and inflicting significant damage. CAEL-101 is a type of monoclonal antibody that reduces or eliminates these deposits and improves organ function.

Author: Elaine Burridge, Freelance Journalist

AstraZeneca’s rare diseases unit Alexion has taken over Caelum Biosciences,...
AstraZeneca’s rare diseases unit Alexion has taken over Caelum Biosciences, gaining access to another rare disease drug, CAEL-1-1, a potential therapy for light chain amyloidosis that has been granted Fast Track status by the US Food and Drug Administration. (c) Alexion

Company

Logo:

AstraZeneca

Byggrad 2/4
15185 Södertälje
Sweden

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.